Furey, Colleen
Scher, Gabrielle http://orcid.org/0000-0002-7571-4791
Ye, Naiqing http://orcid.org/0009-0003-6232-8570
Kercher, Lisa http://orcid.org/0000-0001-6300-0452
DeBeauchamp, Jennifer
Crumpton, Jeri Carol
Jeevan, Trushar
Patton, Christopher http://orcid.org/0000-0002-3685-4337
Franks, John
Rubrum, Adam
Alameh, Mohamad-Gabriel http://orcid.org/0000-0002-5672-6930
Fan, Steven H. Y.
Phan, Anthony T.
Hunter, Christopher A. http://orcid.org/0000-0003-3092-1428
Webby, Richard J. http://orcid.org/0000-0002-4397-7132
Weissman, Drew
Hensley, Scott E. http://orcid.org/0000-0002-2928-7506
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (75N93021C00015, 75N93021C00016, R01AI08686, R01AI126899)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 4 May 2023
Accepted: 6 May 2024
First Online: 23 May 2024
Competing interests
: S.E.H. and D.W. are co-inventors on patents that describe the use of nucleoside-modified mRNA as a platform to deliver therapeutic proteins and as a vaccine platform. S.E.H. reports receiving consulting fees from Sanofi, Pfizer, Lumen, Novavax, and Merck. S.H.Y.F. is an employee of Acuitas Therapeutics, a company focused on the development of lipid nanoparticulate nucleic acid delivery systems for therapeutic applications. The authors declare no other competing interests.